Spruce Biosciences, Inc. (SPRB) stock
SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$40.49−1.76 (-4.17%)
Close on Nov 17, 2026Market cap $116.37MP/E –Yield –
Spruce Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Spruce Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$47.83M. For fiscal 2025 it was -$36.51M. The highest annual figure on record is -$13.11M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$36.51M | – |
| FY2024 | Dec 31, 2024 | -$56.15M | – |
| FY2023 | Dec 31, 2023 | -$51.99M | – |
| FY2022 | Dec 31, 2022 | -$47.28M | – |
| FY2021 | Dec 31, 2021 | -$42.07M | – |
| FY2020 | Dec 31, 2020 | -$29.42M | – |
| FY2019 | Dec 31, 2019 | -$13.11M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$16.51M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.99M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.10M | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.23M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.69M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.49M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.07M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.41M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.04M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.63M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.16M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.66M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.97M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.20M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.11M | – |
| Q3 FY2022 | Sep 30, 2022 | -$11.56M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.88M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.73M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.14M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.40M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.71M | – |
| Q1 FY2021 | Mar 31, 2021 | -$9.82M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.34M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.56M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.39M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.13M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.13M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.56M | – |
See a number that looks wrong?